Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5675094 | 0.99 | CHRNA7 (0.40) | CHRNA7HTR3AHRH3NPC1ALDH1A1 | |
| SCHEMBL6604301 | 0.84 | HTR3A (0.40) | CHRNA7HTR3ASMN1; SMN2 | |
| SCHEMBL6542495 | 0.83 | HRH3 (0.42) | CHRNA7HTR3AHRH3 | |
| SCHEMBL6600859 | 0.83 | HRH3 (0.46) | CHRNA7HTR3AHRH3NPC1ALDH1A1 | |
| Bromide SCHEMBL5673167 | 0.82 | HRH3 (0.41) | CHRNA7HTR3AHRH3 | |
| Oxalic Acid SCHEMBL5673114 | 0.81 | HTR3A (0.36) | HTR3A | |
| SCHEMBL5358073 | 0.81 | CHRNA7 (0.36) | CHRNA7HTR3AALDH1A1RAB9ASMN1; SMN2 | |
| Oxalic Acid SCHEMBL5673576 | 0.80 | UGCG (0.43) | HTR3AHRH3ALDH1A1 | |
| Oxalic Acid SCHEMBL5675074 | 0.80 | HDAC3 (0.48) | HRH3NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL2638565 | 0.77 | HRH3 (0.56) | CHRNA7HTR3AHRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001902-B2 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof | SANOTL-AVENTIS (FR) | 2006-02-21 | — | — | US | disclosed |
| EP-1554283-A1 | 5-SUBSTITUTED 7,9-DIFLUORO-5 I H /I -CHROMENO (3,4-F) QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS, INC. (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1551843-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| EP-1289987-B1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO- 3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-05-19 | — | — | EP | disclosed |
| EP-1289987-B1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO- 3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-05-19 | — | — | EP | disclosed |
| WO-2004033461-A1 | 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004024729-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040029884-A1 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane deirvatives, preparation and therapeutic use thereof | SANOFI (FR) | 2004-02-12 | — | — | US | disclosed |
| US-20040029884-A1 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane deirvatives, preparation and therapeutic use thereof | SANOFI (FR) | 2004-02-12 | — | — | US | disclosed |
| EP-1289987-A1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO- 3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-03-12 | — | — | EP | disclosed |
| EP-1289987-A1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO- 3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092260-A1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO-[3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001092260-A1 | 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO-[3.2.2]NONANE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029884-A1 | 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane deirvatives, preparation and therapeutic use thereof | CBR1, FPR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CHRNA7 2244/4885HTR3A 1703/4885HRH3 631/4885 |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | DBH, CHRNA6, DDT | CHRNA7 13/4885HTR3A 314/4885HRH3 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.